MAM
NKTR icon

Marquette Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Marquette Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,587
Closed -$148K – 183
2024
Q4 		$148K Hold
10,587
– – 0.02% 108
2024
Q3 		$206K Hold
10,587
– – 0.03% 97
2024
Q2 		$197K Sell
10,587
-4,899
-32% -$103K 0.03% 69
2024
Q1 		$217K Buy
15,486
+3,075
+25% +$32.2K 0.04% 69
2023
Q4 		$105K Buy
12,411
+2,519
+25% +$19.1K 0.02% 105
2023
Q3 		$88.4K Hold
9,892
– – 0.02% 111
2023
Q2 		$85.3K Buy
+9,892
New +$105K 0.02% 129

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Marquette Asset Management's NKTR Position: Q1 2025 in Review

Marquette Asset Management sold out of Nektar Therapeutics (NKTR) in Q1 2025, closing a stake of 10,587 shares — an estimated $148K sold.

Marquette Asset Management first reported a position in NKTR in Q2 2023 and held it in 7 quarters. The position peaked at $217K in Q1 2024. 154 funds tracked by Wall St. Rank hold NKTR as of Q1 2025.

  • Marquette Asset Management reported no remaining Nektar Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Marquette Asset Management sold 10,587 Nektar Therapeutics shares in Q1 2025, an estimated $148K.
  • Marquette Asset Management first reported a position in Nektar Therapeutics in Q2 2023 and held it in 7 quarters.
  • Marquette Asset Management's Nektar Therapeutics position peaked at $217K in Q1 2024.
  • 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2025.

Based on Marquette Asset Management's 13F filing for Q1 2025, filed 9 Apr 2025.